IP = investigational product. Revised Protocol No.: 04 Date: 31-May-2019 18 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS 2 SCHEDULE OF ACTIVITIES Table 2-1: Screening Procedural Outline (CA021002) ProcedureScreening Visit (Day -28 to -1)Day -7 to -3 VisitDay -3 to -1 VisitNotes Eligibility Assessments Informed Consent XA participant is considered enrolled only when a protocol specific informed consent is signed. IRT Participant Assignment/Treatment AssignmentXAfter the participant consents, the site will use th e IRT to have the participant number assigned.